A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study
Introduction: COVID-19 virus caused a pandemic in 2020. Since vaccine was the only modality to combat the pandemic, the development of vaccine was fast tracked and made available within 1 year of detecting the virus. Objective: The objective of this study was to assess the safety and clinical effica...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2022;volume=19;issue=4;spage=230;epage=233;aulast=Anwith |
| _version_ | 1811200609012940800 |
|---|---|
| author | Huluvadi Shivalingaiah Anwith Deena Mariyam M Madhusudan Ramegowda Chethana Hulugappa Lakshmi |
| author_facet | Huluvadi Shivalingaiah Anwith Deena Mariyam M Madhusudan Ramegowda Chethana Hulugappa Lakshmi |
| author_sort | Huluvadi Shivalingaiah Anwith |
| collection | DOAJ |
| description | Introduction: COVID-19 virus caused a pandemic in 2020. Since vaccine was the only modality to combat the pandemic, the development of vaccine was fast tracked and made available within 1 year of detecting the virus. Objective: The objective of this study was to assess the safety and clinical efficacy of the COVID-19 vaccines. Materials and Methods: This was a cross-sectional study conducted between June 2021 and September 2021 in Bengaluru using digital data capture. Data pertaining to sociodemographic profile, details of the vaccine administered, adverse events developing within 7 days of vaccine administration, and breakthrough infection were collected. Descriptive statistics such as frequencies, percentages, and mean and standard deviation were used. Inferential statistics such as the Chi-square test were used to test association. Results: The study involved 103 study participants. Totally 100 (97.08) participants had taken Covishield and 3 (2.92) had taken Covaxin. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Ninety-four (91.26%) of study participants had taken at least one dose of COVID-19 vaccine. A total of 62 (60.19%) participants had one or the other adverse reaction following vaccination. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Conclusion: The given COVID-19 vaccines are safe and clinically efficacious with no statistically significant difference between the COVID-19 vaccine type and adverse reaction or with the incidence of breakthrough infection. |
| first_indexed | 2024-04-12T02:06:26Z |
| format | Article |
| id | doaj.art-0d5988d3a9a946158f8f98114d9aa161 |
| institution | Directory Open Access Journal |
| issn | 0976-0016 2213-3682 |
| language | English |
| last_indexed | 2024-04-12T02:06:26Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Apollo Medicine |
| spelling | doaj.art-0d5988d3a9a946158f8f98114d9aa1612022-12-22T03:52:30ZengWolters Kluwer Medknow PublicationsApollo Medicine0976-00162213-36822022-01-0119423023310.4103/am.am_92_22A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional studyHuluvadi Shivalingaiah AnwithDeena MariyamM MadhusudanRamegowda ChethanaHulugappa LakshmiIntroduction: COVID-19 virus caused a pandemic in 2020. Since vaccine was the only modality to combat the pandemic, the development of vaccine was fast tracked and made available within 1 year of detecting the virus. Objective: The objective of this study was to assess the safety and clinical efficacy of the COVID-19 vaccines. Materials and Methods: This was a cross-sectional study conducted between June 2021 and September 2021 in Bengaluru using digital data capture. Data pertaining to sociodemographic profile, details of the vaccine administered, adverse events developing within 7 days of vaccine administration, and breakthrough infection were collected. Descriptive statistics such as frequencies, percentages, and mean and standard deviation were used. Inferential statistics such as the Chi-square test were used to test association. Results: The study involved 103 study participants. Totally 100 (97.08) participants had taken Covishield and 3 (2.92) had taken Covaxin. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Ninety-four (91.26%) of study participants had taken at least one dose of COVID-19 vaccine. A total of 62 (60.19%) participants had one or the other adverse reaction following vaccination. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Conclusion: The given COVID-19 vaccines are safe and clinically efficacious with no statistically significant difference between the COVID-19 vaccine type and adverse reaction or with the incidence of breakthrough infection.http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2022;volume=19;issue=4;spage=230;epage=233;aulast=Anwithbreakthroughcovid-19efficacysafetyvaccine |
| spellingShingle | Huluvadi Shivalingaiah Anwith Deena Mariyam M Madhusudan Ramegowda Chethana Hulugappa Lakshmi A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study Apollo Medicine breakthrough covid-19 efficacy safety vaccine |
| title | A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study |
| title_full | A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study |
| title_fullStr | A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study |
| title_full_unstemmed | A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study |
| title_short | A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study |
| title_sort | study on safety and clinical efficacy of covid 19 vaccines among adults in south india a cross sectional study |
| topic | breakthrough covid-19 efficacy safety vaccine |
| url | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2022;volume=19;issue=4;spage=230;epage=233;aulast=Anwith |
| work_keys_str_mv | AT huluvadishivalingaiahanwith astudyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT deenamariyam astudyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT mmadhusudan astudyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT ramegowdachethana astudyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT hulugappalakshmi astudyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT huluvadishivalingaiahanwith studyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT deenamariyam studyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT mmadhusudan studyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT ramegowdachethana studyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy AT hulugappalakshmi studyonsafetyandclinicalefficacyofcovid19vaccinesamongadultsinsouthindiaacrosssectionalstudy |